tron digital currency price, searches

Since January 1, 2025, Chongqing maternity allowance has been issued to the insured female employees themselves. Recently, Chongqing Medical and Social Security Bureau issued the Notice on Adjusting the Payment Method for Maternity Insurance Benefits, and adjusted the payment method for maternity insurance benefits. From January 1, 2025, the application and method of maternity insurance benefits for the insured shall be applied by the insured himself or his client and issued to him by the medical insurance agency. In order to optimize the processing flow of maternity allowance, the service of "enjoy the maternity allowance immediately upon application" has been opened, that is, when the designated medical institutions in Chongqing settle the maternity medical expenses (delivery and termination of pregnancy), the medical insurance system automatically obtains the maternity-related information to calculate the maternity allowance, and the maternity allowance is paid to the insured after being approved by the medical insurance agency, and the insured or their clients do not need to provide relevant information to the medical insurance agency to declare the offline maternity allowance.Reuters survey: the short bet of won is at the highest level since October 20, 2022; Indian Rupee's short bet reached the highest level since November 17, 2022; Investors reduced their short bets on Philippine peso, Indonesian rupiah, Thai baht and Singapore dollar. 

CEO of Bank of America: The sales and trading business is expected to reach a new high in the fourth quarter, and the investment banking business income will jump. On December 11th, the CEO of Bank of America Brian moynihan said that with the "continuous growth" of transactions, the bank's investment banking business income in the fourth quarter may exceed US$ 1.4 billion, with a year-on-year increase of at least 25%. Moynihan also said that the sales and trading business in the fourth quarter should record a year-on-year growth again, achieving a medium-to-high single-digit growth. The bank also expects that the net interest income will continue to grow, which is expected to achieve the guiding target of $14.3 billion given earlier this year.The Japanese yen faces new risks. Strategists worry that the Bank of Japan may wait until March or later to raise interest rates. A new risk is emerging for the Japanese yen. Foreign exchange strategists in Tokyo warn that the Bank of Japan may wait until March or later next year to raise interest rates. On Wednesday, the market tasted this danger, and the yen fell to its lowest level in more than two weeks as traders responded to a Bloomberg report that the Bank of Japan is known to think that it is no harm to raise interest rates later. The yen only fell to 152.82 against the dollar, and the market is still debating whether the Bank of Japan will take action at its next meeting on December 19 or about a month later. Shusuke Yamada, head of Japan's foreign exchange and interest rate strategy at Bank of America in Tokyo, said that if policymakers put off raising interest rates for a longer time, the situation would be very different. "If the interest rate hike is postponed until March, the yen carry trade is likely to make a comeback," Yamada said on Thursday. "The yen is likely to fall again to a level just below the 157 mark hit in 155 or November."The Korea Composite Index closed up 1.60%.

Leshan Guotou Group and others set up an industrial guidance equity investment fund with a capital contribution of 4.5 billion yuan. According to Tianyancha App, recently, Leshan Jiarong Industrial Guidance Equity Investment Fund Partnership (Limited Partnership) was established, and the executive partner is Leshan Guorong Equity Investment Fund Management Co., Ltd., with a capital contribution of 4.5 billion yuan, and its business scope includes investment activities with its own funds. According to the partner information, the fund is jointly funded by Leshan State-owned Assets Investment and Operation (Group) Co., Ltd., Leshan Finance Bureau and Leshan Guorong Equity Investment Fund Management Co., Ltd.Shanghai Science and Technology Commission: Increase financial support for projects in the fields of scientific instruments, scientific research reagents and technical standards in the Action Plan for Scientific and Technological Innovation, and Shanghai Science and Technology Commission issued the Action Plan for Promoting the Innovative Development of Scientific Instruments and Scientific Research Reagents in Shanghai (2025-2027). The plan points out that financial input should be increased. We will increase support for projects in the fields of scientific instruments, scientific research reagents and technical standards in the Action Plan for Science and Technology Innovation, support technology research and development, product development and standard development, select and fund high-end scientific instruments and scientific research reagent products, and support the construction of technical test and verification platforms, application scenarios and user experience centers. 16. Strengthen financial support. Establish and improve the industrial venture capital mechanism, encourage and guide market capital to participate in industrial development. Give play to the role of the parent fund of the three leading industries and the future industrial fund, encourage social capital investment, support debt financing, mergers and acquisitions, and promote enterprises to become bigger and stronger.The latest collection price of the heavy anticancer star drug Regofibril has dropped to a minimum of more than 4 yuan per tablet. The reporter learned at the scene of the tenth batch of drug collection that the anti-tumor drug Regofibril tablets with annual sales of more than 1 billion yuan have been auctioned by this collection, and the price has almost dropped to between 4 yuan and 6 yuan, which is 90% lower than the price limit. Nanjing Zhengda Tianqing is expected to win the bid in the first round of quotation. Regofibril can treat colorectal cancer, liver cancer and other cancers. Its original research manufacturer is Bayer, which occupies almost all the market share in China. The price of this collection is about 172 yuan per tablet. (science and technology innovation board Daily)